立即開始
Investor4321

RCUS 50+% Potential Gains Friday, January 15-17

Arcus Biosciences, Inc. (NYSE:RCUS)  
Investor4321  
NYSE:RCUS   Arcus Biosciences, Inc.
Fundamental Analysis
3
0
fundamental
RCUS releases phase one clinical trial data for a drug they are developing to treat pancreatic cancer on Friday, January 15-17. Look to buy about a week in advance.
免責聲明

這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。